Four-Year watch: tracking safety of Long-Lasting hemophilia drug
NCT ID NCT04461639
Summary
This study aims to monitor the long-term safety of Jivi, an approved medication for hemophilia A, over at least four years. It will follow 62 patients who are already receiving Jivi regularly to prevent bleeding episodes. Researchers will collect health data during patients' routine doctor visits to check for any side effects or safety concerns.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Many Locations
Multiple Locations, Austria
-
Many Locations
Multiple Locations, Germany
-
Many Locations
Multiple Locations, Greece
-
Many Locations
Multiple Locations, Italy
-
Many Locations
Multiple Locations, Slovenia
-
Many Locations
Multiple Locations, Spain
Conditions
Explore the condition pages connected to this study.